| 36.9 2.72 (7.96%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 46.24 | 1-year : | 51.12 |
| Resists | First : | 39.59 | Second : | 43.77 |
| Pivot price | 37.18  |
|||
| Supports | First : | 32.84 | Second : | 27.32 |
| MAs | MA(5) : | 35.6 |
MA(20) : | 37.51 |
| MA(100) : | 37.62 |
MA(250) : | 24.84 |
|
| MACD | MACD : | -1.3 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 27.7 |
D(3) : | 20 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 49.7 | Low : | 10.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DFTX ] has closed above bottom band by 45.3%. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 38.13 - 38.38 | 38.38 - 38.61 |
| Low: | 33.99 - 34.29 | 34.29 - 34.56 |
| Close: | 36.41 - 36.91 | 36.91 - 37.36 |
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Fri, 14 Aug 2026
Driehaus Capital trims percentage stake in Definium Therapeutics (DFTX) to 5.36% - Stock Titan
Thu, 19 Feb 2026
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 - Business Wire
Sat, 17 Jan 2026
Deinium Therapeutics (DFTX) Is Up 8.7% After Rebrand And DT120 Anxiety Pipeline Update - What's Changed - Yahoo Finance
Sat, 17 Jan 2026
Definium Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | DFTX | CA24477V1058 - marketscreener.com
Thu, 15 Jan 2026
Definium Therapeutics (DFTX) Stock Price, News & Analysis - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 134 (M) |
| Shares Float | 125 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 88 (%) |
| Shares Short | 8,970 (K) |
| Shares Short P.Month | 10,640 (K) |
| EPS | -3.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.84 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.7 % |
| Return on Equity (ttm) | -64.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -168 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -10.76 |
| PEG Ratio | 0 |
| Price to Book value | 5.39 |
| Price to Sales | 0 |
| Price to Cash Flow | -29.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|